Clinical outcome measures in multiple sclerosis

Journal of the Neurological Sciences

Volumn 259, Issue 1-2, 2007, Pages 118-122

  Amato, Maria Pia ^a   Portaccio, Emilio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Multiple sclerosis; Outcome measure; Rating scales

Indexed keywords

AMBULATION INDEX; ARTICLE; CAMBRIDGE MULTIPLE SCLEROSIS BASIC SCORE; ENVIRONMENTAL STATUS SCALE; EXPANDED DISABILITY STATUS SCALE; HUMAN; INCAPACITY STATUS SCALE; MEDICAL INSTRUMENTATION; MEDICAL PRACTICE; MS IMPAIRMENT SCALE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS FUNCTIONAL COMPOSITE; NEUROLOGIC EXAMINATION; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; RATING SCALE; SCRIPPS NEUROLOGICAL RATING SCALE;

CLINICAL TRIALS; DISABILITY EVALUATION; HUMANS; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT (HEALTH CARE); REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 34447096458     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2006.06.031     Document Type: Article

References (30)

1. Amato M.P., and Ponziani G. Quantification of impairment in MS: discussion of the scales in use. Mult Scler 5 4 (1999) 216-219
2. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 11 (1983) 1444-1452
3. Sipe J.C., Knobler R.L., Braheny S.L., Rice G.P., Panitch H.S., and Oldstone M.B. A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology 34 10 (1984) 1368-1372
4. Ravnborg M., Gronbech-Jensen M., and Jonsson A. The MS Impairment Scale: a pragmatic approach to the assessment of impairment in patients with multiple sclerosis. Mult Scler 3 1 (1997) 31-42
5. Rudick R., Antel J., Confavreux C., Cutter G., Ellison G., Fischer J., et al. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol 42 3 (1997) 379-382
6. International Federation of Multiple Sclerosis Societies. Minimal record of disability for multiple sclerosis (1985), National Multiple Sclerosis Society, New York
7. Sharrack B., and Hughes R.A. The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler 5 4 (1999) 223-233
8. Hauser S.L., Dawson D.M., Lehrich J.R., Beal M.F., Kevy S.V., Propper R.D., et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 308 4 (1983) 173-180
9. Mumford C.J., and Compston A. Problems with rating scales for multiple sclerosis: a novel approach-the CAMBS score. J Neurol 240 4 (1993) 209-215
10. Weinshenker B.G., Bass B., Rice G.P., Noseworthy J., Carriere W., Baskerville J., et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 112 Pt 6 (1989) 1419-1428
11. Weinshenker B.G., Issa M., and Baskerville J. Meta-analysis of the placebo-treated groups in clinical trials of progressive MS. Neurology 46 6 (1996) 1613-1619
12. Amato M.P., Fratiglioni L., Groppi C., Siracusa G.F., and Amaducci L. Interrater reliability in assessing functional systems and disability on the Kurtzke scale in multiple sclerosis. Arch Neurol 45 (1988) 746-748
13. Goodkin D.E., Cookfair D., Wende K., Bourdette D., Pullicino P., Scherokman B., et al. Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research Group. Neurology 42 4 (1992) 859-863
14. Amato M.P., Groppi C., Siracusa G.F., and Fratiglioni L. Inter and intra-observer reliability in Kurtzke scoring systems in multiple sclerosis. Ital J Neurol Sci Suppl 6 (1987) 129-131
15. Confavreux C., Compston D.A., Hommes O.R., McDonald W.I., and Thompson A.J. EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry 55 8 (1992) 671-676
16. Amato M.P., Grimaud J., Achiti I., Bartolozzi M.L., Adeleine P., Hartung H.P., et al. European validation of a standardized clinical description of multiple sclerosis. J Neurol 251 12 (2004) 1472-1480
17. Lechner-Scott J., Brunnschweiler H., and Kappos L. The Study Steering Committee. Is it possible to achieve cross-cultural European agreement in the assessment of neurological deficits? First experience in the European interferon beta-1b trial for secondary progressive MS. J Neuroimmunol 42 Suppl 1 (1995)
18. Sharrack B., Hughes R.A., Soudain S., and Dunn G. The psychometric properties of clinical rating scales used in multiple sclerosis. Brain 122 Pt 1 (1999) 141-159
19. Cutter G.R., Baier M.L., Rudick R.A., Cookfair D.L., Fischer J.S., Petkau J., et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 122 Pt 5 (1999) 871-882
20. Miller D.M., Rudick R.A., Cutter G., Baier M., and Fischer J.S. Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life. Arch Neurol 57 9 (2000) 1319-1324
21. Cohen J.A., Fischer J.S., Bolibrush D.M., Jak A.J., Kniker J.E., Mertz L.A., et al. Intrarater and interrater reliability of the MS functional composite outcome measure. Neurology 54 4 (2000) 802-806
22. Hobart J., Kalkers N., Barkhof F., Uitdehaag B., Polman C., and Thompson A. Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite. Mult Scler 10 1 (2004) 41-46
23. Cohen J.A., Cutter G.R., Fischer J.S., Goodman A.D., Heidenreich F.R., Jak A.J., et al. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol 58 6 (2001) 961-967
24. Solari A., Radice D., Manneschi L., Motti L., and Montanari E. The multiple sclerosis functional composite: different practice effects in the three test components. J Neurol Sci 228 1 (2005) 71-74
25. Hoogervorst E.L., Kakers N.F., Uitdehaag B.M., and Polman C.H. A study validating changes in multiple sclerosis functional composite. Arch Neurol 59 1 (2002) 113-116
26. Hobart J., Lamping D., Fitzpatrick R., Riazi A., and Thompson A. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain 124 Pt 5 (2001) 962-973
27. Hobart J.C., Riazi A., Lamping D.L., Fitzpatrick R., and Thompson A.J. How responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? A comparison with some other self report scales. J Neurol Neurosurg Psychiatry 76 11 (2005) 1539-1543
28. Hoogervorst E.L., Zwemmer J.N., Jelles B., Polman C.H., and Uitdehaag B.M. Multiple Sclerosis Impact Scale (MSIS-29): relation to established measures of impairment and disability. Mult Scler 10 5 (2004) 569-574
29. Noseworthy J.H., Vandervoort M.K., Wong C.J., and Ebers G.C. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group. Neurology 40 6 (1990) 971-975
30. Francis D.A., Bain P., Swan A.V., and Hughes R.A. An assessment of disability rating scales used in multiple sclerosis. Arch Neurol 48 3 (1991) 299-301